An increasing number of targeted agents have entered early pediatric trials, such as HDM-201 (NCT02780128), an MDM2 inhibitor applied to neuroblastoma, and ALRN-6924 (NCT03654716), a dual MDM2/MDMX inhibitor applied to solid tumors in children. This evidence concerns the gene MDM2 and neuroblastoma.